EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese subjects with Transthyretin Amyloid Cardiomyopathy

Trial Identifier: D8450C00005
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: May 2026
Study Completion Date: January 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100037
CN Beijing, CN, 100730
CN Beijing, CN, 100191
CN Beijing, CN, 100034
CN Beijing, CN, 100029
CN Changsha, CN, 410013
CN Changsha, CN, 430033
CN Changsha, CN, 410008
CN Chengdu, CN, 610072
CN Chengdu, CN, 610041
CN Chongqing, CN, 400010
CN Chongqing, CN, 400042
CN Guangzhou, CN, 510100
CN Guangzhou, CN, 510062
CN Ha'er bin, CN, 150001
CN hangzhou, CN, 310052
CN Hangzhou, CN, 310003
CN Hangzhou, CN, 310014
CN Jinan, CN, 250001
CN Nanchang, CN, 330006
CN Shanghai, CN, 200032
CN suzhou, CN, 215006
CN Taiyuan, CN, 030001
CN Wuhan, CN, 430060
CN Wuhan, CN, 430030
CN Xi'an, CN, 710061